Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2021
Reporting Period: Single event date (November 4, 2021)
Business Context: The filing serves to distribute a slide deck (Exhibit 99.1) intended for use in a company presentation. The registrant is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach a presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial position or operations are reported in this specific filing. The document solely announces the availability of a presentation deck.
Guidance, Outlook, and Risks
- Management Commentary: The Company states that the information in the attached presentation is summary in nature and should be considered in the context of other SEC filings and public announcements.
- Forward-Looking Statements: The Company explicitly undertakes no duty or obligation to publicly update or revise the information contained in the presentation, though it may do so at management's discretion.
- Regulatory Note: The filing clarifies that furnishing this information does not constitute an admission of materiality under Regulation FD.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Presentation) for specific operational or clinical data not detailed in this cover letter.
- Verify the most recent financial position by consulting the latest Form 10-K or 10-Q, as this 8-K contains no financial data.
- Confirm the trading symbol (INMB) and exchange (NASDAQ) for current market status.
- Note the "Emerging Growth Company" status, which may affect financial reporting requirements and disclosure obligations.